Robustness to both genetic and environmental change is an emergent feature of living systems.
Introduction
In eukaryotes, the molecular chaperone HSP90 facilitates the folding of diverse protein clients (1) . These clients are implicated in nearly all aspects of organismal growth and development, and thus HSP90 is highly connected in genetic networks (1) (2) (3) . As a heat shock protein and negative regulator of heat shock transcription factors (4), HSP90 is also linked to the external environment and enables environmental signaling through chaperoning receptors and downstream signaling components in many pathways (1, 3, 5, 6) .
The interaction of HSP90 with its protein clients affords them additional physicochemical stability, allowing clients to accommodate mutations that may otherwise impact their function (7) (8) (9) (10) (11) . Indeed, across the mammalian lineage, including humans, genes encoding HSP90 client kinases carry significantly more and more deleterious variation that those encoding non-client kinases (10) . The higher evolutionary rate of HSP90 clients mirrors results with other chaperones (8, 9, (12) (13) (14) (15) (16) , suggesting that protein stabilization generally increases evolutionary rates through relaxed selection on new mutations in clients (7) .
Consequently, HSP90 inhibition compromises client protein folding and causes deleterious phenotypic effects, which may be exacerbated by genetic variation residing in the genes encoding these clients. This phenomenon is distinct from HSP90-dependent effects on epigenetic phenomena (17) (18) (19) or the frequency of de novo mutations (2, (20) (21) (22) (23) (24) (25) . HSP90 perturbation through mutation, pharmacological inhibition, or increased temperature reveals distinct, strain-specific morphological aberrations and altered quantitative traits in flies, plants, fish, and yeast (26) (27) (28) (29) (30) (31) (32) (33) (34) . In worms, naturally varying HSP90 levels predict the penetrance of mutations in several signaling proteins (35, 36) . In humans, HSP90 enables the function of several mutated oncogenic proteins, resulting in the chaperone serving as a drug target in cancer (6, (37) (38) (39) (40) .
HSP90 can affect both penetrance (i.e. frequency of an aberrant trait associated with a genetic variant) and expressivity (i.e. severity of an aberrant trait associated with a genetic variant) (25, 29, 31, 33, 35, 36) . The effect of HSP90 on variant penetrance and expressivity is the basis of the capacitor hypothesis which posits that HSP90 allows accumulation of genetic variation, which remains phenotypically silent until released upon stress or targeted HSP90 perturbation. However, two controversies, prompted by recent studies, remain to be resolved, the first concerning the nature of the variants that can be buffered by the chaperone (41) , and the second concerning the relative contributions of HSP90-dependent de novo variation to phenotype (22, 24) .
As to the first, the increased evolutionary rate of HSP90 clients across the mammalian lineage suggests that HSP90-buffered variation tends to be relatively old and remains present in populations in the face of selection (10) . It is less clear how HSP90 affects new genetic variants or variant combinations that have not been exposed to selection. To address this question, studies in yeast and plants have studied hundreds of divergent segregant lines generated from crosses of outbred strains; these segregant lines represent new variant combinations that have not been exposed to long-term selection (28, 32, 33) . In sum, the results argue that HSP90 buffers such new genetic combinations.
A recent study compared several yeast mutation accumulation lines, each carrying ~4 single nucleotide variants, to yeast strains isolated from natural environments to address whether HSP90 acts similarly on newly arising mutations and older standing variation (41) . Focusing on trait variance rather than trait frequencies or trait means, Geiler-Samerotte and colleagues argue that HSP90 fails to confer mutational robustness for alleles that have not experienced selection.
In contrast to the earlier studies (28, 32, 33) , these authors also report diminished rather than increased phenotypic variance in response to HSP90 inhibition in yeast segregant lines, which they posit casts doubt on current strategies to target HSP90 in cancer therapies.
Thus far, no study has evaluated the effects of HSP90 on very large numbers of newly introduced mutations in an isogenic background, a strategy that should resolve these contradictions. Here, we introduced thousands of random mutations into Col-0 plants, the Arabidopsis thaliana reference genotype, and into Col-0 plants with reduced HSP90 levels (42) or treated with an HSP90 inhibitor (29) . If HSP90 buffers at least some of the newly introduced mutations, we should, and did, observe a greater frequency and severity of mutant phenotypes in HSP90-reduced plants. The HSP90-responsive phenotypes in mutagenized seedlings commonly resembled those arising in the unmutagenized Col-0 background at much lower frequency (29) , consistent with the notion that variants in a limited number of client proteins contribute to HSP90-dependent phenotypes as opposed to invoking complex higher-order epistasis across genetic networks. Broadly, our results support the idea that HSP90 buffers new genetic variation.
Lastly, our study design allowed us to address the controversy whether HSP90-dependent phenotypes are largely a consequence of de novo mutations arising in HSP90-reduced lines as recently argued (22) . Although HSP90 inhibition increases the frequency of certain mutations (2, 20, 21, 23, 24, (43) (44) (45) (46) (47) (48) , we find no evidence that the majority of HSP90-dependent phenotypes observed here arises due to HSP90-dependent de novo mutations. In sum, our results resolve the two remaining controversies surrounding the HSP90 capacitor hypothesis.
Results

HSP90 perturbation increases penetrance of embryonic lethal mutations
We used ethyl methanesulfonate (EMS) mutagenesis to generate large numbers of new mutations in the A. thaliana reference strain Col-0 and in two Col-0-derived HSP90-RNAi lines, HSP90 RNAi-A1 and HSP90 RNAi-C1 (42) (Figure 1A) . The construct in the HSP90 RNAi-C1 plants interferes with the function of multiple HSP90 paralogs to produce more severe HSP90-dependent phenotypes than the construct in HSP90 RNAi-A1 plants, which interferes only with the heat-inducible HSP90.1 paralog (42).
The EMS-mutagenized seeds (M 1 generation) were transferred to soil and grown to maturity ( Figure 1A) . To assess the mutagenesis efficiency and the frequency of embryonic lethal mutations, we counted the number of live and dead seeds (M 2 generation) produced by the M 1 plants (Figure 1B, C) (49) . As expected, higher concentrations of EMS led to significantly higher rates of embryonic lethal mutations relative to untreated Col-0 controls ( Figure 1C) .
Values for seed viability and embryonic lethal mutations were reproducible across experiments. Table) . However, EMSmutagenized HSP90 RNAi-A1 plants did not show more embryonic lethal mutations than EMSmutagenized Col-0 plants ( Figure 1C) .
A trivial explanation for the greater number of embryonic lethal mutations in the HSP90
RNAi-C1 background is either that these plants were more deeply mutagenized than Col-0 plants or that fewer mutations were repaired. HSP90 chaperones proteins that function in DNA repair (50, 51) , and as HSP90 inhibition also increases the rate of certain mutations (2, (20) (21) (22) (23) (43) (44) (45) (46) (47) (48) , even equivalent EMS treatments may produce more mutations in the HSP90 RNAi-C1 background. Alternatively, as predicted under the capacitor hypothesis (25, 31, (52) (53) (54) , some EMS-generated mutations may acquire greater penetrance when HSP90 is inhibited and therefore result in embryonic lethality.
To distinguish whether increased penetrance or mutation quantity causes the increased embryonic lethality in the HSP90-reduced line, we performed whole-genome sequencing of six randomly selected EMS-mutagenized M 2 HSP90 RNAi-C1 and six randomly selected M 2 Col-0 plants. Both backgrounds showed similar genomic distributions and numbers of unique mutations per individual plant ( Figure 1D, E, S1 Fig) . Each M 2 individual showed ~1000 highconfidence, private single nucleotide variants ( Figure 1E , S1 Table, x-coverage >= 5, derived allele coverage >= 2). We conclude that the significantly greater number of embryonic lethals observed in the EMS-mutagenized HSP90-reduced M 2 progeny are likely due to the increased penetrance of the newly introduced mutations because of reduced HSP90 buffering.
HSP90 perturbation increases the frequency of severely aberrant phenotypes across generations
Having established that newly introduced mutations are more likely to cause lethality in HSP90-reduced plants than in controls, we examined the effects of HSP90 reduction on the frequency of aberrant morphological phenotypes. As such plant phenotypes are qualitative in nature (29), we used a mutant scoring index to estimate the frequency of 16 complex early seedling traits, categorized by severity (Figure 2A, B) .
We first examined the frequency of these aberrant phenotypes in the M 1 We used the highly specific HSP90 inhibitor geldanamycin (GdA) (Whitesell, 1994) to examine whether a similar trend held for the EMS-mutagenized Col-0 M 1 plants when HSP90 was inhibited pharmacologically. Indeed, GdA treatment significantly increased phenotype frequency and severity in this population ( S2 Fig). We conclude that HSP90 perturbation increases the penetrance and expressivity of heterozygous or somatic mutations that affect seedling morphology phenotypes.
Second, we tested the response to HSP90 perturbation, both pharmacologically and genetically, in the M 2 generation using the same mutant phenotype index ( Figure 3A) . In the M 2 generation, with the newly introduced mutations segregating, some will be homozygous and others heterozygous. HSP90 perturbation should increase the expressivity and penetrance of these mutations and thereby cause a higher frequency of severely aberrant morphological phenotypes. Consistent with this expectation, we observed a significantly greater frequency of severe phenotypes among the EMS-mutagenized seedlings grown with the HSP90 inhibitor compared to unmutagenized seedlings and mutagenized seedlings grown with the DMSO solvent ( Figure 3B ). This observation manifests statistically as an interaction between GdA treatment and mutagenesis in their effect on phenotype frequency; the strongest such interaction was observed at an intermediate GdA dose (Fisher's exact test: p-value <1.0E-15, OR=4.6). Genetic HSP90 perturbation yielded similar results: the M 2 HSP90 RNAi-C1 seedlings produced significantly more aberrant phenotypes than comparable M 2 Col-0 seedlings (Fisher's exact test: p-value <1.0E-15, OR=8.8) ( Figure 3C ). We conclude that HSP90 perturbation increases the frequency and severity of aberrant phenotypes after mutagenesis.
Tracking the HSP90-dependent nature of aberrant morphological phenotypes across generations
We asked whether the phenotypes from newly introduced mutations are indeed HSP90-dependent, i.e. whether or not they would be expressed when HSP90 is fully functional. As it is not possible to examine a single plant both with and without HSP90 perturbation, we generated M 3 offspring from M 2 parents that displayed aberrant phenotypes under HSP90-reduced or control conditions (see Materials and Methods). Although some of the newly generated EMS mutations will segregate in the M 3 offspring, this approach generates groups of sibling plants with a similar mutation background that can be examined under either control or HSP90-reduced conditions. Specifically, we selected M 2 plants with the deformed aerial organ phenotype on DMSO medium (DM plants, Figure 4 A, B) or GdA medium (GM plants). Deformed aerial organs are readily identified and can be a consequence of HSP90 perturbation (29, 42) . In addition to the deformed aerial organ phenotype, we also examined the M 3 progeny of the 22 GM and 10 DM plants for the other 15 phenotypes (Figure 2A , B) because more than one phenotype was noted for many parental M 2 plants (S3 Table) .
Under standard growth conditions, 20 M 3 lines showed significantly increased frequencies of deformed aerial organs, with more DM lines (7 out of 10) than GM lines (13 out of 22) producing this phenotype ( Figure 4A, B) . The lesser heritability of this trait in the GM lines is consistent with HSP90 perturbation increasing penetrance and expressivity of newly introduced variation in the parental lines.
Next, we asked how many of these lines showed an HSP90-dependent response in the frequency of this phenotype. Nine of 13 GM lines showed significant HSP90-dependence in the expression of the aberrant phenotype, whereas only one out of seven DM lines did. This DM line and seven out of the nine significantly HSP90-responsive GM lines showed low frequencies of deformed aerial organs in control conditions (i.e. DMSO) and significantly increased phenotype frequencies when HSP90 was perturbed ( Figure 4C , GM, dark red lines, DM, bright red line).
This HSP90-dependent increase in phenotype frequencies agrees with several previous studies (29, 30, 34, 36, 56) . We also found two GM lines with a significantly decreased frequency of the aberrant phenotype ( Figure 4C , GM dark blue lines, Fisher's exact test: p-adj<0.05, OR<0.03), reminiscent of previous findings that HSP90 perturbation can conceal the phenotypic consequences of underlying variation (26, 28, 32, 41) .
As some parental M 2 plants showed other aberrant phenotypes in addition to the selected phenotype, it was not surprising to find these phenotypes also in their offspring ( Figure 4B ).
Only two DM M 2 plants with deformed aerial organs showed additional defects; both produced (29, 56) , upon HSP90-perturbation, unmutagenized Col-0 wildtype plants tended to show dwarf phenotypes, lesions on cotyledons, discoloration, and epinastic organs among others. Second, about half of the mutagenized M 3 also showed these phenotypes in response to HSP90 perturbation, albeit often at far higher frequency. Assuming that the HSP90-dependent phenotypes observed in wild-type Col-0 plants reflect dysfunctional client proteins (25, 57) , this observation suggests that some of the newly introduced HSP90-dependent variants reside in genes encoding these clients or network nodes closely associated with them. Third, selection for the deformed aerial organ trait in the mutagenized lines increased the phenotype frequencies dramatically in some lines, consistent with a genetic, possibly multigenic basis.
Lastly, certain traits, such as aborted seedlings and severe developmental delay that are observed only infrequently in unmutagenized Col-0, were strongly responsive to HSP90 perturbation in the mutagenized M 3 lines, indicative of problems in early plant development and consistent with the increased embryonic lethality observed in the M 1 generation. Taken together, our results indicate that at least some newly introduced mutations readily lead to heritable HSP90-responsive phenotypes.
Mapping HSP90-responsive loci containing newly introduced mutations
To further explore the genetic basis of the HSP90-responsive deformed aerial organ trait, we applied a bulk segregant approach, notwithstanding the significant challenges due to the large number of introduced EMS mutations and the partially penetrant, HSP90-responsive nature of the trait. As the aberrant phenotype was both partially penetrant in the mutagenized lines and present at low levels in Col-0 wild-type seedlings, we would not expect a derived allele frequency of 100% indicating the approximate location of the causal mutation, as expected in a traditional bulk segregant analysis (58) . Rather, we expected a contiguous increase in derived allele frequency (DAF) above background levels expected in an F 2 population in HardyWeinberg equilibrium (DAF=0.5).
We selected two M 3 lines, GM6 and GM9, with significantly increased penetrance of this phenotype under HSP90-reduced conditions (OR>4.5). Single GM6 and GM9 M 3 individuals with deformed aerial organs were backcrossed to Col-0 wild-type plants to generate heterozygous F 1 populations. A randomly selected individual from each cross was selfed to generate segregating F 2 populations for both backgrounds (Figure 5A, B; S5 Fig). As this backcross will dilute phenotype-associated variation, fewer seedling with deformed aerial organs were observed in standard growth conditions while phenotype frequencies in HSP90-reduced conditions stayed high ( Figure 5C; S5 Fig) . To map the HSP90-responsive EMS mutations in the GM6 and GM9 backgrounds, we sequenced pools of approximately 120 F 2 individuals displaying deformed aerial organs upon HSP90 perturbation. For both backgrounds, we found regions with elevated derived allele frequency, consistent with the presence of newly introduced HSP90-responsive mutations ( Figure 5D; S5 Fig; S6 Fig) .
For the GM6 F 2 population, one notable region contained eight consecutive new mutations with elevated derived allele frequency. Six of these did not reside in coding regions, but one (Chr1:5,407,084 C=>T) was a missense mutation (proline to leucine) in the MYB family transcription factor AT1G15720 ( Figure 5D, S4 Table) . For the GM9 F 2 population, one region contained six consecutive new mutations with elevated derived allele frequency. Five of these resided in coding regions, each in different genes, and each was a missense mutation ( S5 Fig), two of which had negative blosum62 scores, suggesting deleterious effects (S4 Table) .
To determine how likely these observations were to occur by chance (i.e. no new mutation conferred increased phenotypic penetrance upon HSP90-reduction), we performed simulations in which 240 gametes (representing 120 random F 2 individuals, carrying two haploid pseudochromosomes each) were generated from a simulated F 1 individual, heterozygous for n mutations, assuming one recombination event per chromosome. Of these 240 pseudochromosomes, we sampled x, reflecting actual experimental x-coverage (read depth, in GM6 mean x-coverage =77; in GM9 mean x-coverage =54). Out of 100 such simulations, none A mutation associated with altered response to HSP90 perturbation would result in an increase in the derived allele frequency for an entire region (haplotype block) containing multiple SNVs, as we describe above for GM6 and GM9. Therefore, we were conservative in annotating SNVs as likely EMS-derived and removed any SNVs that were present pre-mutagenesis in our Col-0 and HSP90-reduced lines compared to the reference genome. To do so, we generated sequence data for Col-0 and the HSP90-RNAi C1 line, examining the number of derived alleles (compared to the A. thaliana reference genome) in single plants of both backgrounds (two Col-0 plants, two HSP90 RNAi-C1 plants). As single individuals were sequenced to ~10x coverage, we counted bases only with derived allele frequency of 1 (homozygous for derived allele). We found similar numbers of derived alleles in all four plants (S1 Table) . There was no evidence supporting higher numbers of single nucleotide mutations in HSP90 RNAi-C1 compared to wild-type Col-0.
Although HSP90 perturbation can lead to de novo germline (and likely somatic)
mutations, it appears unlikely that these mutations contributed significantly to the greater penetrance and expressivity of aberrant phenotypes in the HSP90-reduced seedlings. This assertion is further supported by the fact that the unmutagenized HSP90 RNAi lines showed similar levels of embryonic lethality as Col-0 wild-type (Figure 1 B, C) . Moreover, we reproduced the results generated with the HSP90 RNAi-C1 line with pharmacological inhibition of HSP90 in mutagenized Col-0 seedlings. The HSP90 inhibitor is supplied to the growth medium and taken up during seed germination and growth; the seeds contain fully formed
embryos. An HSP90-dependent de novo mutation affecting these embryos would be somatic and hence unlikely to be heritable. Taken together, our results support the argument that the increased frequency and severity of aberrant phenotypes in response to HSP90 perturbation is due to increased penetrance and expressivity of newly introduced EMS mutations rather than germline de novo mutations arising in the HSP90 RNAi-C1 line.
Discussion
Our data argue that HSP90 buffers the penetrance and expressivity of newly introduced genetic variation in A. thaliana. Penetrance effects included an increased frequency of embryonic lethals, and expressivity effects included more severe aberrant morphological phenotypes.
Tracking phenotypes across generations, we found several lines that showed heritable aberrant morphological phenotypes in an HSP90-dependent manner. As it does for standing genetic variation (25, 28-31, 34, 59-61), HSP90 plays a role in buffering phenotype against newly introduced genetic variation, which has not been exposed to selection.
These observations are broadly consistent with past studies on new genetic combinations in yeast and plants (28, 32, 33) . However, one recent yeast study (41) concludes that phenotypic variance associated with newly introduced mutations typically decreases under HSP90 inhibition (i.e. "potentiation", 25, 26, 62) . Here, we argue the opposite: the more parsimonious interpretation of the available data is that HSP90 commonly buffers new mutations.
Our argument relies on multiple lines of evidence. First, we screened a large number of mutations. The mutagenized and sequenced M 2 individuals carried between 800 to 2,000 new mutations, such that we screened on the order of tens of millions of new mutations, many of them through multiple generations. In contrast, the 94 mutation accumulation lines tested in the recent yeast study carry on average only four single nucleotide mutations per haploid genome (41) . Second, we demonstrated the substantial heritability of HSP90-responsive traits, suggesting that these phenotypes are likely to be the effect of genetic mutations rather than stochastic effects. Third, we identified candidate loci associated with an HSP90-responsive phenotype in two independent lines. Fourth, we used two methods (genetic and pharmacological) to perturb HSP90, whose results corroborated each other, demonstrating that the findings are not a consequence of either geldanamycin's off-target effects or a peculiarity of the HSP90 RNAi lines. Fifth, all mutations were assayed immediately after introduction into the A. thaliana genome, such that our analysis should represent the full spectrum of phenotypic effects of new mutations, including those that would be quickly purged by selection. Last, in prior studies, we demonstrate that the effects of revealed HSP90-responsive variation on phenotype means outweigh its effects on phenotype variance by as much as a magnitude, consistent with the capacitor hypothesis' premise that HSP90-dependent phenotypes can be acted upon by natural selection (33) .
However, the present study has some limitations. First, the semi-quantitative phenotype categories make estimates of heritability subject to threshold effects, likely decreasing heritability estimates. Second, aside from embryo lethality, we assayed highly complex developmental phenotypes, and the effects of HSP90 on these phenotypes may be less relevant in the unicellular yeast, which does not experience a prolonged ontogeny. Third, EMS mutagenesis may introduce a different spectrum of mutations than those that arise spontaneously in natural populations.
That HSP90 can buffer new mutations is also supported by newly emerging data. For example, saturation mutagenesis of the non-client yeast transcription factor Ste12 revealed HSP90-responsive Ste12 variants; these variants were rare and position-dependent; moreover, they were implicated in the environmentally-sensitive balance between the mutually exclusive traits of yeast mating and invasion that are governed by Ste12 (63) . Similarly, recurrent HSP90-dependent variants in oncogenes are highly sequence-specific and rare (60, (64) (65) (66) .
Notwithstanding these results on the buffering of new mutations, standing variation is likely a more significant actor in most HSP90-dependent phenotypes (11, 25-34, 56, 59 ).
Materials and Methods
Plant Growth Conditions:
Seedlings of the Columbia-0 (Col-0) ecotype were used as a wildtype reference; this stock has been propagated in the Lindquist and Queitsch labs since 1994 and was originally provided by Brian Keith. The HSP90 RNAi-A1 and HSP90 RNAi-C1 were generated in this background (42 Seedlings were grown as previously described (29, 42) . Seedlings of indicated genotypes and treatments were scored blindly for the described morphological phenotypes (Figure 2 ).
Seedlings were photographed with a Canon Power Shot S5 IS camera, pictures were edited using Adobe Photoshop CC 2017. Edits addressed image size, brightness, and contrast and did not alter depiction of seedling phenotypes. Sequencing libraries were generated using 50 ng of input DNA using the Nextera (Illumina) sample kit according to the manufacturer's instructions. Libraries were quality checked on the Agilent 2100 bioanalyzer using a DNA high-sensitivity chip (Agilent). The samples were sequenced by Genewiz on an Illumina HiSeq (100bp paired-end reads).
WGS reads were aligned to the TAIR10 release genome (http://www.arabidopsis.org/) using the default parameters of BWA (68) . Aligned reads with mapping quality less than 35 were discarded. A VCF file was generated using SAMtools (http://samtools.sourceforge.net). Variants were further filtered for minimum coverage = 5 and minimum derived allele coverage = 2. We filtered each VCF file for unique mutations (i.e. unshared with any other sample within either
Col-0 or HSP90 RNAi-C1 genotypes) as these were likely due to the EMS treatment. After identifying unique and private SNVs, we determined the number of total non-reference transitions and transversions for each individual. For analysis in mutagenized backgrounds, a similar filtering process was performed, where again we determined unique, unshared nonreference variants in each sequenced individual. See S1 grown on HSP90-reduced growth medium (0.5 µM GdA), seedlings with deformed aerial organs were selected and pooled (n>90). Total DNA was extracted from these pools using the CTAB method; DNA was quantified using the Qubit HS dsDNA assayed. Sequencing libraries were generated using 10 ng input DNA with the Nextera (Illumina) sample kit. Libraries were quality checked on the Agilent 2100 bioanalyzer using a DNA high-sensitivity chip (Agilent). The samples were sequenced using an Illumina NextSeq in 150bp paired-end run.
Because our Col-0 line has been bulk-propagated in our lab since 1994, wild-type Col-0 individuals contain derived SNVs with respect to the published TAIR10 reference sequence at varying frequencies. We identified these background SNVs by sequencing two pooled Col-0 individuals at ~8 x-coverage, allowing us to remove such derived SNVs from our list of EMSgenerated mutations. Additional background Col-0 SNVs were identified by comparing SNVs in the deeply sequenced (>50 x-coverage each) F 2 populations derived from GM6 and GM9.
Derived SNVs found in both populations are unlikely to be due to EMS treatment.
With the pooled F 2 plants, we are measuring derived allele frequency at likely EMS-generated SNVs, a task that requires much greater read depth. Furthermore, SNVs present in the unmutagenized parents (M 0 ) relative to TAIR10 reference genome must be carefully filtered out.
As we are attempting to identify regions rather than single SNVs with elevated derived allele frequency, erroneously discarding or including certain SNVs should not prevent the identification of regions containing causative SNVs.
Our filtering pipeline proceeded as follows:
First, reads from the F 2 pools were mapped to the TAIR10 reference genome using BWA (default parameters Next, SNVs were identified in a pool of M 0 Col-0 seedlings to identify background SNVs as well as in the two pools of F 2 seedlings (aberrant seedlings grown on GDA-reducing media, for both the GM6 and GM9 strains). All bases with any evidence of an alternate allele were identified (derived allele frequency > 0). We excluded background SNVs (DAF>0) identified (i) in the Col-0 pool (n=1,022,369), and (2) in both the two deeply sequenced GM6 and GM9 GDAtreated F 2 pools (n=1,093,093). There was very little overlap between these sets of background SNVs (n=78,805), indicating that the vast majority of the former set were either spuriously identified as polymorphic --which is certainly possible given the low sequencing coverage --or neither of the individual seeds that were mutated to give rise to the GM6 and GM9 lines contained the derived allele --also possible, given that many of these flagged bases had relatively low derived allele frequency.
Among this filtered set of EMS-derived SNVs identified in the two F 2 pools, we then attempted to remove SNVs erroneously arising due to sequencing error by removing SNVs with less than two reads indicating the derived allele. Reads collected typically had per-bp Phred quality score of 20 or more (error rate < 1/1,000), therefore the probability of two reads presenting an identical error is low.
We also attempted to remove SNVs erroneously arising due to mapping error by removing SNVs with unusually low x-coverage. The mean x-coverage in the GDA-treated F 2 pools was high (GM6 F 2 x-coverage=77; GM9 F 2 x-coverage=54) and followed an approximately lognormal distribution, per base. Specifically, we required each such bp to have xcov greater than mean(log10(x-coverage)) -2*sd(log10(x-coverage)).
For our final analysis, we examined only likely EMS mutations with derived allele frequency > 0.2.
Statistical analysis:
All statistical analyses were performed in R Version 3.2.5. Comparisons of seedling aberrant phenotype frequencies were performed with Fisher's exact test (S2 Table) .
Comparisons of embryonic lethality were modeled with a Poisson regression using a general linear model. Student's t-tests performed for seed viability. When appropriate, p-values were adjusted using the R function "p.adjust," with method= "fdr." The results of all statistical tests performed are in S2 Table. Figure Legends F2 individuals displaying this trait on HSP90-reduced conditions (n=94) were sequenced.
Derived allele frequencies (y-axis) were estimated as the fraction of reads supporting the derived allele divided by the number of reads mapping to a given locus (see Materials and Methods).
Dark gray box indicates the centromere and light gray box represents pericentromeric regions (chr1:12,000,000-18,000,000; chr2:1,000,000-7,500,000; chr3:11,000,00-17,000,000; chr4:1,800,000-7,500,000; chr5:10,000,000-17,000,000). Dashed red line represents derived allele frequency of 0.675. Dashed black line represents expected derived allele frequency of 0.5.
The candidate locus contains one SNV (chr1:5,407,084 C=>T) encoding a missense mutation (proline to leucine) in the MYB family transcription factor AT1G15720.
